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considered a pathology.3,4 It has been observed 
that the incidence of PFO in the population de‑
creases with age and is about 34% in the first 3 
decades of life, 25% in the fourth to eighth de‑
cades, and 20% in the ninth decade.3‑5 This is ex‑
plained by late spontaneous closures of PFO or 
greater mortality in patients with PFO.4 When 
pressure in the right atrium is increased, the duct 
may open and a short right ‑left shunt may occur; 
moreover, potential embolic material may enter 
the systemic circulation.1‑8 In addition, thrombus 
formation and release from the PFO channel is 
also possible, especially in the presence of atrial 
septal aneurysm (ASA). Vasoactive substances, 
Introduction The patent foramen ovale (PFO) 
is a remnant of fetal circulation, which in ute‑
ro allows oxygenated blood to flow between 
the right and left atrium. As a result of pres‑
sure changes in the atria after birth, the fora‑
men ovale in most cases closes during the first 
2 years of life.1,2 However, in some cases, it does 
not close completely and a channel remains be‑
tween the septum primum and the septum se‑
cundum. The channel has an average length 
of about 5 mm and can be of different shapes. 
Based on the results of autopsy, the prevalence 
of PFO in the general population is estimated 


















The presence of patent foramen ovale (PFO) was found to be associated with a number of medical conditions, 
including embolic stroke and recurrent transient neurological defects. The closure of PFO remains 
controversial; however, in recently published guidelines from the European Association of Percutaneous 
Cardiovascular Interventions in collaboration with 7 other European societies, which extensively refer to 
the latest randomized clinical trials, it is explicitly recommended to perform percutaneous PFO closure 
in the prevention of recurrent thromboembolic events.
In connection with the above facts and expected increasing number of PFO closure procedures, the joint 
expert group of the Association of Cardiovascular Interventions and the Grown ‑Up Congenital Heart 
Disease Section of the Polish Cardiac Society developed the following consensus opinion in order 
to standardize the principles of diagnosis, indications, methods of performing procedures, and postoperative 
care in relation to Polish conditions and experiences.
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observational studies have suggested that clo‑
sure of PFO in patients with ischemic events, 
compared with antiplatelet or anticoagulant 
therapy, reduced the  incidence of recurrent 
stroke.48‑50 Recently, the results of several pro‑
spective randomized clinical trials were also pub‑
lished and they tested the hypothesis regard‑
ing the efficacy of transcatheter PFO closure in 
the prevention of ischemic cerebral and periph‑
eral thromboembolic events.51‑53 They confirmed 
the long ‑term clinical efficacy of PFO closure.54‑56
On the other hand, there is still a lot of con‑
troversy and ambiguity regarding qualifying pa‑
tients for the procedure, type of device, and op‑
timal peri‑ and postoperative treatment. Euro‑
pean and American recommendations to date 
have not recommended routine closure of PFO in 
stroke prevention / TIA, but they were published 
before new randomized trials appeared.57‑59 
However, the recently published guidelines of 
the European Association of Percutaneous Car‑
diovascular Interventions and 7 other Euro‑
pean societies have been published, which ex‑
tensively refer to the latest randomized clini‑
cal trials, explicitly recommend percutaneous 
PFO closure in preventing repeated thrombo‑
embolic events.60
In connection with the above and expect‑
ed increasing number of PFO closure proce‑
dures, the group of experts of the Association 
for Cardiovascular Interventions and the Sec‑
tion of Grown ‑up Congenital Heart Disease of 
the Polish Cardiac Society developed the follow‑
ing consensus opinion in order to standardize 
the principles of diagnosis, indications, proce‑
dures and postoperative care in relation to Pol‑
ish conditions and experiences.
Current state of scientific knowledge: ran-
domized trials The results of numerous, al‑
though nonrandomized, observational studies 
indicated a decrease in the incidence of recur‑
rent stroke in patients after ESUS who had PFO 
closure compared with those treated only phar‑
macologically.61‑63 Unfortunately, the negative 
results of the first 3 randomized trials (CLO‑
SURE 1 [Closure or Medical Therapy for Cryp‑
togenic Stroke with Patent Foramen Ovale], PC 
which normally are degraded in the lungs, may 
also play an important role in various pathologies, 
and in those with PFO, they affect cerebral circu‑
lation similarly to nitrogen bubbles in divers.6‑8
For many years there has been a debate about 
the relationship between PFO and thromboem‑
bolic complications, including the most seri‑
ous one, that is, ischemic stroke.4‑10 Cryptogen‑
ic stroke or, according to the current nomen‑
clature, embolic stroke of undetermined source 
(ESUS) is responsible for almost half of all isch‑
emic strokes in patients younger than 55 years, 
and PFO is found in this group even in 40% to 
61% of patients (diagnostic criteria, see TAble 1).11,12 
It was also found that the presence of PFO in‑
creases 3‑fold the risk of a recurrent ischemic 
event.5 ‑7 The  relationship between ischemic 
stroke has been proved not only in younger (<55 
years of age) but also in older patients.12
The concept of crossed (paradoxical) embo‑
lism as a result of infiltration of embolic mate‑
rial through the persistent connection between 
the right and left atria as a cause of stroke, tran‑
sient ischemic attack (TIA) or peripheral embo‑
lism, including myocardial infarction, has been 
well documented in the literature.3‑7,13,14 In addi‑
tion to ESUS, there is also a suggestion of a caus‑
al relationship between PFO and such disease en‑
tities as: platypnea ‑orthodeoxia,15,16 decompres‑
sion illness,17‑19 migraine with aura,20‑34 or high‑
‑altitude pulmonary edema.35‑37 Relationships be‑
tween PFO and peripheral embolism have also 
been described.38‑42 It has also been found that 
PFO is an independent risk factor for death and 
adverse clinical events in patients with massive 
pulmonary embolism.43 Some anatomical factors 
also increase the risk of paradoxical embolism. 
In addition to the above ‑mentioned ASA, these 
are: eustachian valve, Chiari network, or a large 
spontaneous left ‑right leak.44‑45
Transcatheter percutaneous PFO closure 
was first introduced in 1992 by Bridges et al,46 
and in 1997 the most popular 2‑disc Amplatzer 
device was implanted for the first time.47 Since 
then, a number of studies have been conduct‑
ed on the efficacy and safety of closing PFO 
in patients with ESUS or peripheral embo‑
lism using various types of devices. Long ‑term 
Table 1 Diagnostic criteria of embolic stroke of undetermined source (formerly cryptogenic stroke). Adapted 
from Hart et al.10
Ischemic nonlacunar stroke detected by CT or MRI (subcortical infarct ≥1.5 cm on CT or ≥2 cm on MRI)
Absence of significant atherosclerotic plaques in extra- or intracranial arteries (causing >50% luminal stenosis)
No major risk of cardioembolic source of embolism (atrial fibrillation / flutter, intracardiac thrombus identified, 
myxoma or other cardiac tumors, mitral stenosis, recent acute myocardial infarction, valvular vegetations, 
LVEF <30%)
Absence of other specific cause of stroke (eg, vasculitis, dissection, migraine / vasospasm, drug abuse, poisoning)
Abbreviations: CT, computed tomography; LVEF, left ventricular ejection fraction; MRI, magnetic resonance imaging
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of the test can be obtained by adding a little 
blood to the mixture.69 The Valsalva maneuver 
is used to temporarily increase the right atri‑
um pressure. This maneuver should be carried 
out for about 10 seconds, the echocardiograph‑
ic contrast should be given for about 8 seconds, 
and then the recording of the echocardiograph‑
ic image should also begin. For people unable to 
properly perform this maneuver, gentle pressure 
of the epigastric region for about 10 to 20 seconds 
is recommended, with release immediately before 
contrast administration. Visualization of air bub‑
bles passing through the channel is an unequiv‑
ocal confirmation of PFO, but the appearance of 
air bubbles in the left atrium in the third to sixth 
cardiac cycle after contrast administration is also 
considered diagnostic. The subsequent appear‑
ance can be associated with the presence of com‑
munication between high and low circulation on 
another level (in some centers, bubbles appear in 
the left atrium only during the first 3 cardiac cy‑
cles). The sensitivity of the transesophageal ex‑
amination with contrast in the detection of PFO 
is estimated at about 90%.72‑74
In many cases, 3‑dimensional imaging during 
transesophageal echocardiography allows to ac‑
curately depict the anatomy of the PFO channel 
and to visualize the passage of bubbles during 
the contrast examination. However, it should be 
noted that images obtained during contrast exam‑
ination have significantly lower time resolution.75
Right ‑to‑left leakage can also be detected us‑
ing the transcranial Doppler examination76 by 
performing contrast recording (as during echo‑
cardiography) during both free breathing and 
during the Valsalva maneuver. For this pur‑
pose, a 2 MHz transducer, most often located 
in the temporal region, is used. This allows to 
visualize the flow in the anterior / middle and 
posterior cerebral arteries on the examined side 
in about 80% of patients (in other cases, it may 
be necessary to use other acoustic windows). 
Higher test accuracy is obtained using power 
M ‑mode modality. This test is characterized by 
high sensitivity and specificity (97% and 93%, 
respectively); however, it is not possible to de‑
termine the level of leakage.7 7 The advantage of 
transcranial Doppler is the possibility to quan‑
titatively assess the degree of leakage and the 
scale by Spencer et al73 is commonly used for that 
purpose (degrees 0–5; grade 3 and more confirm 
the presence of a leak) (TAble 3).
Interventional technique: available clo-
sure devices Transcatheter PFO closure is 
performed in patients under general anesthe‑
sia, with the use of analgosedation or under lo‑
cal anesthesia, most often using the right com‑
mon femoral vein access.4‑5,78 During the pro‑
cedure heparinization is required with the tar‑
get activated clotting time of 250 to 300 sec‑
onds. Prophylactic intravenous administration 
Trial [Percutaneous Closure of Patent Foramen 
Ovale in Cryptogenic Embolism] and the results 
of a short follow‑up from the RESPECT [Pat‑
ent Foramen Ovale Closure or Medical Thera‑
py after Stroke] study) regarding the effective‑
ness of transcatheter closure of PFO in second‑
ary prevention of cerebrovascular incidents in 
patients after ESUS were disappointing,51‑53 al‑
though they aroused a lot of controversy as well 
as doubts with regards to methodology.64 De‑
spite the fact that 2 published meta ‑analyses of 
the above studies indicated the advantage of in‑
terventional treatment over conservative treat‑
ment, the qualification of patients for such pro‑
cedures remained controversial for many years, 
especially among neurologists.64‑66
The publication of the results of 3 random‑
ized studies in 2017 (REDUCE, CLOSE, and long‑
‑term follow ‑up of RESPECT trial) comparing in‑
terventional treatment with pharmacotherapy 
in the group of patients after ESUS and PFO ap‑
pears to be a real breakthrough.54‑56 In 2018, an‑
other randomized DEFENSE ‑PFO study was pub‑
lished that also confirmed the effectiveness of in‑
terventional therapy in high ‑risk PFO patients.67
The most important clinical data of the above 
studies indicating the advantage of intervention‑
al therapy over pharmacological treatment are pre‑
sented in TAble 2 .
Patent foramen ovale diagnosis Sensitivity 
and specificity of transthoracic echocardiogra‑
phy in the detection of PFO are 46% and 99%, 
respectively.68 The accuracy of the method in‑
creases when imaging with the second harmon‑
ic component. It also depends on the laborato‑
ry’s experience and adopted criteria (the num‑
ber of microbubbles registered in the left atri‑
um and the time of their appearance).69
Transesophageal echocardiography is a more 
detailed examination.69,70 The assessment should 
include the  size and thickness of the  sep‑
tum secundum, the length of the PFO chan‑
nel, the width (wall separation) of the channel, 
the distance between the PFO and the superi‑
or vena cava, the mobility of the atrial septum 
(presence of ASA), as well as the presence of addi‑
tional structures / cavities within the right atri‑
um. In some cases, it is also possible to visual‑
ize the flow in color Doppler imaging, depend‑
ing on the right ‑left and left ‑right atrial pres‑
sure ratio.71 Usually, however, to confirm the pa‑
tency of the PFO channel it is necessary (as in 
the transthoracic examination) to use an echo‑
cardiographic contrast agent with a simultane‑
ous right atrial pressure maneuver.
A commonly used contrast agent in the diagno‑
sis of PFO is a mixture of saline (0.9% NaCl) with 
air (to avoid contamination, it is recommended 
to take air through an antibacterial filter). An ad‑
ditional increase in the stability of the obtained 
air bubbles and an increase in the sensitivity 
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Table 2 Summary of the results of the latest randomized clinical trials regarding intervention closure of patent foramen ovale in patients 
after cryptogenic stroke





RESPECT5 4 Previous cryptogenic stroke; 
age, 18–60 y;  







• Aspirin with 
dipyridamole
• Recurrent stroke: 
18 patients in intervention 
group and 28 patients 
in conservative group 
(relative risk reduction, 
45%; HR, 0.55; 95% CI, 
0.31–0.999; P = 0.046)
• Recurrent stroke (after 
ASCOD scale consideration) 
– 10 patients in intervention 
group 23 patients 
in conservative group 
(relative risk reduction, 
72%; HR, 0.38; 95% CI, 
0.18–0.79; P = 0.007)
Subgroups analysis: 
patients with atrial 
septal aneurysm 
and large right ‑to‑
-left shunt benefit 





CLOSE55 Previous cryptogenic stroke with high‑
‑risk PFO (atrial septum aneurysm or 
large left -to -right shunt), age, 18–60 
y; n = 663 patients
Randomization:
1) Group 1, 1:1:1 randomization 
(without contraindications to OAT, 
n = 524):
• PFO closure with long ‑term 
antiplatelet therapy
• Antiplatelet therapy alone
• OAT
2) Group 2, 1:1 randomization (with 
contraindications to OAT, n = 129):
•  PFO closure with antiplatelet therapy










• In PFO closure group there 
was no stroke; in 
conservative treatment 
group, 14 strokes (HR, 0.03; 
95% CI, 0–0.26; P <0.001).
• The cumulative 5‑year risk 
of stroke based 
on  Kaplan–Meier curves 
was 0% in the invasive 
group and 4.9% 




TIA, or peripheral 
embolism) was less 
frequent in patients 





(3.4% vs 8.9%; 
HR, 0.39; 95% CI, 
0.16–0.82; 
P = 0.01).
REDUCE56 Previous cryptogenic stroke with PFO; 









• Recurrent stroke: 6 patients 
(1.4%) in the intervention 
group and 12 patients 
(5.4%) in the conservative 
group (reduction by 77%) 
(HR, 0.23; 95% CI, 
0.09–0.62; P = 0.002).
• Clinically apparent stroke 
or the occurrence of new, 
clinically silent ischemic foci 
on imaging studies: 
22 patients (5.7%) in whom 
PFO was closed and 20 
patients (11.3%) in 
the group treated only with 
antiplatelet agents (relative 
risk reduction 0.51; 95% CI, 
0.29–0.91; P = 0.04)
Number of new 
clinically silent 
ischemic foci 
similar in both 
groups: 17 (4.4%) 
in the intervention 
group and 8 (4.5%) 
in the antiplatelet 
group (P = 0.97)
DEFENSE‑
‑PFO67
Previous cryptogenic stroke with 
high‑risk PFO (size ≥2 mm, excessive 
mobility of the atrial septum); n = 
120; 1:1 randomization; 






Composite endpoint: stroke, 
TIA, cardiac death, TIMI‑
-defined major bleeding.
In the PFO group without 
incidents; 
in the conservatively treated 
group: 12.9% of incidents, 
including 5 strokes, 
1 intracranial bleeding, 
1 TIA, and 2 major bleeding 
(log rank P = 0.013)
In the intervention 




1 pericardial fluid, 
1 pseudoaneurysm
Abbreviations: AF, atrial fibrillation; ASCOD, atherosclerosis, small -vessel disease, cardiac pathology, other causes; CLOSE, Patent Foramen Ovale Closure or Anticoagulation 
versus Antiplatelets after Stroke; DEFENSE ‑PFO, Cryptogenic Stroke and High‑Risk Patent Foramen Ovale; HR, hazard ratio; OAT, oral anticoagulation therapy; PFO, patent 
foramen ovale; REDUCE, Patent Foramen Ovale Closure or Antiplatelet Therapy for Cryptogenic Stroke; RESPECT, Long‑Term Outcome of Patent Foramen Ovale Closure or 
Medical Therapy after Stroke; TIA, transient ischemic attack; TIMI, Thrombolysis In Myocardial Infarction
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This is to avoid air embolization into the heart. 
In subsequent stages of the procedure, the device 
is implanted through the delivery sheath. Final‑
ly, the delivery system is detached after careful 
verification of the device position and stability 
(so‑called tug test). There is an increasing num‑
ber of different types of devices dedicated to 
transcatheter FPO closure (FIGUre 1). The vast ma‑
jority are occluders with a 2‑disk structure and 
similar implantation principles.80 The principles 
of sizing and implantation as well as the char‑
acteristic features of selected devices are pre‑
sented in TAble 4. The technology based on trans‑
catheter placement of the suture to seal the PFO 
channel is currently at the early stages of im‑
plementation into clinical practice (eg, NobleS‑
titch EL, Heartstitch, Fountain Valley, Califor‑
nia, United States).
At the final stage of the procedure, hemosta‑
sis is obtained with a subcutaneous Z‑type su‑
ture or alternatively a traditional pressure ban‑
dage dressing, rarely a dedicated closing device.81
Periprocedural imaging Echocardiograph‑
ic imaging is used to identify PFO and to se‑
lect those patients for whom PFO is a poten‑
tial threat.
Qualification to intervention treatment TEE is 
the gold standard for PFO imaging. The study al‑
lows to identify the separation of plaques of fo‑
ramen ovale channel and estimate the severity 
of right ‑left leakage. Measurements of the PFO 
channel should be made in the longitudinal pro‑
jection high in the short axis at rest and during 
the Valsalva maneuver after the contrast is ap‑
plied to the ulnar vein.
Patients with PFO and right ‑to‑left leakage 
at rest or in the Valsalva maneuver are eligible 
for a procedure to close the defect. Only plaque 
separation without leakage visualized at this lev‑
el cannot be considered a significant pathology. 
Such case can be recognized as a partly patent 
PFO, that is, not fully patent channel that does 
not cause leakage.
Imaging during the procedure TEE is crucial 
during percutaneous closure of PFO. At the ini‑
tial stage, it allows confirming the passage of 
the catheter through the PFO channel, in “dif‑
ficult,” winding, or narrow channels, the pen‑
etration is only possible under the control of 
TEE. During implantation and expansion of 
the device, TEE allows for precise visualization 
of the delivery system and disks. Before releas‑
ing the implant, one should confirm the correct 
position of the device, the presence of a possible 
residual leak, as well as visualize the anatomi‑
cal structures near the device—the aorta, mi‑
tral valve, circumflex artery, roof of the atrium—
and exclude possible collision of these struc‑
tures with the device. It is important to check 
of antibiotic (eg, cephazolin, 1 g IV) is recom‑
mended 30 to 60 minutes before the procedure.
The 0.035‑inch soft J ‑tip guidewire is inserted 
under fluoroscopic guidance into the right atri‑
um from where it is directed by a multi ‑purpose, 
Amplatz or Cournand (4.5–6F) catheter through 
the PFO channel into the left atrium. The end of 
the catheter is placed in the left upper pulmo‑
nary vein. In exceptional situations, puncture of 
the atrial septum may be required, especially in 
case of a long PFO channel or coexistence of small 
leaks through type II atrial septal defects (ASD).79
After exchanging for a 3‑cm J ‑tip stiff guide‑
wire (eg, Extra Stiff 0.035 Amplatz Wire), a ded‑
icated device sheath (8‑9F) is inserted into 
the left atrium. The end of the delivery sheath 
is placed in the central part of the left atrium 
and the dilator with the guidewire are removed. 
The dilator removal should be slow with the prox‑
imal end of the introducer sheath kept below 
heart level until abundant blood backflow is seen. 
Table 3 Recommendations for basic diagnostic methods of patent foramen ovale
It is recommended to diagnose PFO using TEE with an echocardiographic contrast agent 
and with the right atrial pressure maneuver simultaneously.
The presence of right ‑to ‑left shunt can also be detected using TCD by contrast recording 
(as in echocardiography) during both free breathing and during the Valsalva maneuver.
Abbreviations: TCD, transcranial Doppler; TEE, transesophageal echocardiography, others, see TAble 2
Figure 1 A – Amplatzer PFO Occluder, Abbott Vascular; B – Amplatzer Multifenestrated 
(Cribiform) Septal Occluder, Abbott Vascular; C – Delivery sheath Amplatzer TorqVue 45°; 
D – GORE CARDIOFORM Septal Occluder, Gore Medical; E – Delivery knob of GORE 
CARDIOFORM Septal Occluder, Gore Medical; F – Figulla Flex II, Occlutech; G – CeraFlex PFO 
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of PFO have not been proved in specially de‑
signed clinical trials. The treatment regimens 
used in everyday clinical practice are the result of 
expert consensus, best reflected in the protocols 
of large recently published clinical trials, indicat‑
ing the potential benefit of interventional treat‑
ment compared with conservative treatment in 
patients with secondary prevention of embolism 
to the central nervous system. The common point 
of anticoagulation therapy after PFO closure 
present in the RESPECT, CLOSE, and REDUCE 
protocols is the perioperative use of dual anti‑
platelet therapy for up to 3 months (1–6 months 
can be used).54‑56 After that, it is recommended 
to continue treatment with a single antiplatelet 
drug, most often acetylsalicylic acid (TAble 7), for 
an indefinite period (at least for 5 years).
In rare cases, when OAC is required in a pa‑
tient undergoing PFO closure, therapy should be 
individualized depending on the risk of bleed‑
ing and the risk of recurrence of thromboem‑
bolic events (eg, use only OAC or an additional 
antiplatelet agent for 3 months after surgery).
Complications of transcatheter patent fora-
men ovale closure Percutaneous closure of 
PFO is an effective and safe procedure. A meta‑
‑analysis of 10 studies (total number of patients, 
1355) showed the occurrence of major and small 
perioperative complications in 1.5% and 7.9%, 
respectively.62
Complications of the procedure can be divided 
into nonspecific that can occur during any type 
of intervention or diagnostic procedure (vascu‑
lar, infectious, thromboembolic complications, 
air embolism, transient perioperative cardiac 
arrhythmias), and specific to this procedure.
Specific complications of PFO closure include 
residual leakage, thromboembolic complications, 
including recurrent stroke or TIA, embolization 
of the occlusion device, damage to heart struc‑
tures, arrhythmias, damage to the device com‑
ponents, and very rarely atrial wall erosion with 
possible aortic wall damage.84
The frequency of residual leaks is estimated 
at around 2.3% to 15% and depends on the di‑
agnostic methods used and the time of assess‑
ment. Over time, a decrease in the residual leak‑
age frequency is observed, which should be asso‑
ciated with the progressive implant endothelial‑
ization. Leak is asymptomatic, but may increase 
the risk of recurrent stroke or TIA, which is es‑
timated to be around 0% to 4.9%.62
Thromboembolic complications usually oc‑
cur in the  first months after implantation. 
The thrombosis associated with the device re‑
quire intensified anticoagulation.85 Complete 
withdrawal of the thrombus has been described. 
Large thrombi that may embolize may be an in‑
dication for surgical removal.
Some patients experience migraine head‑
aches after PFO closure. These are most often 
the occluder’s stability. In each case, the appear‑
ance of pericardial fluid and possible other com‑
plications, such as thrombi formation, should 
be monitored.
Postprocedural follow ‑up Postoperative control 
should include transthoracic echocardiography 
performed regularly up to a year after surgery, 
followed by an annual follow ‑up. In case of doubt 
on the transthoracic examination, the diagno‑
sis should be supplemented with TEE. Echocar‑
diographic examination should show the posi‑
tion of the device, the presence of possible resid‑
ual leak, assess the presence of fluid in the peri‑
cardium or other possible complications such as 
thrombi or vegetations.
Indications for patent foramen ovale clo-
sure Qualification for PFO closure should be 
routinely preceded by a neurological consul‑
tation. The neurologist’s opinion is crucial for 
the correct diagnosis of ESUS and further qual‑
ification of the patient for interventional clo‑
sure of PFO or pharmacological treatment. Gen‑
erally, in cases where there are indications for 
long‑term oral anticoagulation (OAC; atrial fi‑
brillation, some cases of venous thromboem‑
bolism, thrombophilia), pharmacological treat‑
ment rather than transcatheter closure of PFO 
is indicated. However, patients with OAC used 
for concomitant pulmonary embolism or at high 
risk of recurrence of thromboembolic events de‑
spite anticoagulant therapy may be considered 
as candidates for PFO closure.57,82,83
Recognition of a causal relationship between 
PFO and stroke is based on an assessment of 
the likelihood of other potential causes of em‑
bolism and may be difficult. Tests that exclude 
other causes of stroke, such as 24‑hour Holter 
electrocardiography monitoring (in patients at 
high risk for atrial fibrillation) and carotid ul‑
trasound, should be performed. Laboratory tests 
for thrombophilia are also indicated. To assess 
the clinical probability of casual role of PFO in 
stroke can be the Risk of Paradoxical Embolism 
(RoPE) score.57 Diagnostic workup of PFO and 
other significant anatomical conditions as well 
as risk factors are presented in detail in sections 
Patent foramen ovale diagnosis and Periproce‑
dural imaging. TAble 5 presents summaries of clini‑
cal and anatomical factors that increase the like‑
lihood of ischemic stroke in people with PFO.
Based on available randomized controlled tri‑
als and observational studies, the experts rec‑
ommend percutaneous transcatheter closure of 
PFO in the indications shown in TAble 6.
Anticoagulation and antiplatelet treatment 
in patients after interventional patent fora-
men ovale closure The selection of the appro‑
priate type and duration of anticoagulant thera‑
py in patients undergoing transcatheter closure 
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patients who had this type of ailment before 
the procedure.
The displacement of the closing device is 
one of the most serious periprocedural compli‑
cations. It occurs with a frequency of 0.7% to 
1.2%,86,87 much less frequently than in the case 
of ASD closure. The device may embolize into 
both the left and right heart cavities. Percuta‑
neous implant removal is possible using sys‑
tems dedicated to remove foreign bodies (vas‑
cular loops, forceps, bioptomes). Migration of 
the closure device may be an indication for its 
operational removal. Late implant migrations 
are extremely rare.
During implantation of the device, the walls 
of the atria can be injured and result in peri‑
cardial effusion or even cardiac tamponade. 
Small bleeding may spontaneously stop; larg‑
er may require decompression by pericardial 
puncture or cardiac surgery. Echocardiograph‑
ic assessment of the pericardium should be 
one of the important elements of monitoring 
of the procedure.
An implanted occludder can interact with sur‑
rounding cardiovascular structures. This may 
result in chafing of the heart and tamponade. 
Abrasion of the aortic wall can cause aortic atri‑
al fistula.
Arrhythmias after implantation of PFO oc‑
cluder may be manifested by atrial additional 
beats, less often by transient AV conduction 
disturbances.88,89 Implantation of PFO devic‑
es significantly increases the likelihood of atri‑
al fibrillation. However, it is definitely small‑
er than in the case of ASD occlusion, where 
hemodynamic disorders coexist in addition 
to the implant’s impact. In the CLOSE study, 
the risk of atrial fibrillation was 4.6% as com‑
pared with 0.9% in the pharmacologically treat‑
ed group.55 In case of atrial fibrillation, treat‑
ment should be in accordance with the cur‑
rent standards.90
Isolated cases of damage or fracture of a pre‑
vious‑generation implant have been reported. 
They may remain asymptomatic or, if affected 
by heart structures, be the cause of their inju‑
ry. Device configuration abnormalities on echo‑
cardiography are indications for radiological flu‑
oroscopy, which is the most accurate in assess‑
ing device damage.91
Treatment of patients after interventional 
closure of patent foramen ovale Manage‑
ment of patients after percutaneous PFO clo‑
sure includes: 1) antiplatelet therapy; 2) follow‑
‑up visits after surgery with clinical and echo‑
cardiographic assessment; 3) prevention of in‑
fective endocarditis.
The purpose of follow ‑up visits is to assess 
the tightness of PFO closure and to diagnose 
possible complications. The guidelines show 
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Table 5 Anatomical and clinical risk factors of recurrent stroke in patients with patent foramen ovale
Anatomical risk factors
• ASA with septum shift >10 mm
• Large left -to -right shunt (passage of >25 contrast bubbles during the Valsalva maneuver or spontaneous right -to -left shunt at rest >4 mm on color 
Doppler TEE)
• Presence of Eustachian valve >10 mm or Chiari network
• Long PFO tunnel
Clinical risk factors
• Recurrent episodes of ESUS or TIA
• Multiple ischemic lesions in brain CT / MRI
• History of DVT / PE or thrombophilia
• Ischemic event associated with the Valsalva maneuver
• Ischemic event connected with long travel / immobilization
• Simultaneous pulmonary and systemic embolism
• Thromboembolic event during antiplatelet or anticoagulation therapy
Abbreviations: ASA, atrial septum aneurysm; DVT, deep vein thrombosis; ESUS, embolic stroke of undetermined source; MRI, magnetic resonance imaging; PE, pulmonary 
embolism; others, see TAbleS 1–3
Table 6 Recommendations for transcatheter patent foramen ovale closure in prevention of recurrent thromboembolic ischemic events
Transcatheter PFO closure should be performed in patients <60 years old
•  After ESUS or TIA with confirmed ischemic lesions in neuroradiological imaging (CT or MRI) or after an episode of peripheral embolism (including 
myocardial infarction)
•  With PFO with at least 1 anatomical or clinical high -risk factor confirmed by contrast TEE examination
Transcatheter PFO closure PFO should be considered in patients <60 years old
•  After ESUS or with TIA with confirmed ischemic lesions in neuroradiological imaging (CT or MRI) or after an episode of peripheral embolism 
(including myocardial infarction)
•  With PFO confirmed by contrast TEE
Transcatheter PFO closure should be considered in secondary prevention in patients
•   After the episode of decompression divers disease and presence of PFO confirmed by contrast TEE
•  After the episode of HAPE and presence of PFO confirmed by contrast TEE
Transcatheter PFO closure may be considered, especially if high ‑risk factors are present, in primary prevention in
•   Deep or professional divers
•  Mountain climbers, alpinists
•  Professional, military and aerobatic pilots
Transcatheter PFO closure may be considered, especially if high ‑risk factors are present, in patients with
•  Platypnoe -orthodeoxia syndrome
•  Exercise desaturation (after excluding causes other than PFO)
•   Sleep -apnea syndrome
Transcatheter PFO closure should not be performed in
• Primary prevention of ischemic episodes in patients with the presence of PFO without ESUS / TIA or ischemic lesions in neuroradiological imaging
•  Patients with other causes of stroke (carotid atherosclerosis, atrial fibrillation) which, despite PFO coexistence, more likely explaining stroke
•  Patients with indications for chronic anticoagulation (except of patients with simultaneous incidence of pulmonary embolism)
•  Patients with migraine headaches without changes in neuroradiological studies
Abbreviations: HAPE, high‑altitude pulmonary edema; others, see TAbleS 1–3 and 5
Table 7 Recommendations for anticoagulation and antiplatelet therapy in patients undergoing transcatheter patent foramen ovale closure
During the procedure, unfractionated heparin should be used in all patients at a dose of approx. 60 IU/kg of bw as bolus under ACT control to achieve 
a time in the range of 250–300 seconds.
Antiplatelet therapy should be initiated before or immediately after the procedure. In the absence of prior drug saturation, a 300 mg of ASA and 
300 mg of clopidogrel loading dose is recommended.
After the procedure, dual antiplatelet therapy should be used at a maintenance dose of 75 mg (both ASA and clopidogrel) for a period of 1–3 months. 
After this period of time, it is recommended to continue treatment with one antiplatelet drug for the indefinite period, usually ASA.
Abbreviations: ACT, activated clotting time; others, see Table 5
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(conditional status according to mrisafety.com). 
For Figulla Flex II (Occlutech, Helsingborg, Swe‑
den), magnetic resonance imaging is safe even 
immediately after the procedure.
Recommendations for training physicians to 
perform patent foramen ovale closure To 
ensure optimal results, PFO closure should be 
performed in experienced centers that routine‑
ly perform these types of procedures and oth‑
er structural heart interventions. Cooperation 
with a neurologist is obligatory. Data from regis‑
tries regarding ASD and PFO closure procedures 
show that both individual operators and centers 
with a small number of procedures performed 
annually have worse treatment results.94 Train‑
ee operators should have the theoretical knowl‑
edge and technical skills required to safely per‑
form this procedure to ensure the least number 
of complications. In the United States, in accor‑
dance with the recommendations of the Food 
and Drug Administration, the training program 
includes, in addition to theoretical training, 25 
procedures under the supervision of an experi‑
enced operator.
It seems that in the case of experienced in‑
terventional cardiologists, 15 to 20 PFO clo‑
sure procedures performed independently, but 
under the supervision of an experienced oper‑
ator, should be required.95,96
The team of experts of the Association of Car‑
diovascular Interventions (ACVI) recommends 
that the training physician should acquire the‑
oretical knowledge regarding the indications 
and qualifications for surgery, patient prepa‑
ration, perioperative pharmacotherapy as well 
as the selection of the device size and peri‑ and 
postprocedural pharmacotherapy. It is also nec‑
essary to acquire knowledge of the possible com‑
plications, their prevention, and treatment. We 
recommend observing the procedures during 
the didactic workshops (see the list of confer‑
ences recommended by ACVI), conducted by ex‑
perienced operators, in an interactive format. 
In addition, the acquisition of practical experi‑
ence with the equipment before the procedure, 
or the possibility of performing the procedure 
on a simulator can be a very good preparation 
for the training physicians.
After such training, preferably in a center 
with extensive experience, the training opera‑
tor should perform a minimum of 15 PFO closure 
procedures independently but under the super‑
vision of an experienced operator. In addition, 
the ACVI team of experts recommends that in 
a center that carried out less than 25 PFO clo‑
sure procedures, the procedures should be per‑
formed in the presence of an experienced oper‑
ator (proctor) to train staff and to avoid com‑
plications during the first procedures. Howev‑
er, the presence of cardiac surgery department 
on site is not required (TAble 9).
postprocedural control, hence each center uses 
its own follow ‑up protocol (TAble 8). The echocar‑
diographic and clinical assessment of the pa‑
tient is usually made on day 1, after 4 to 6 weeks, 
after 6, and 12 months after surgery and then 
every year, indefinitely. In case of any abnor‑
mality, the treatment of the patient and subse‑
quent controls should be determined individu‑
ally. It is important to develop standard proce‑
dures in each center.
During the  control visit, in addition to 
the physical examination, electrocardiography 
and transthoracic echocardiography should be 
performed. If abnormalities in the TTE are found 
or suspected, TEE examination should be per‑
formed. In some centers, TEE is routinely done 
4 to 6 weeks after surgery. If arrhythmias are 
found or suspected, Holter monitoring should 
be performed.
According to the general principles from 
the guidelines, prophylaxis of infective en‑
docarditis should be used for 6 months after 
surgery, and in patients with persistent re‑
sidual leakage or other defects (eg, mitral re‑
gurgitation), lifetime prophylaxis should be 
considered.92
Return to full physical activity including play‑
ing sports is allowed in uncomplicated cases 
4 weeks after implantation of the device.93
Magnetic resonance imaging is safe (for 
1.5–3 T devices) in patients 6 weeks after im‑
plantation of the  nitinol ‑containing device 
Table 8 Recommendations regarding the treatment after the intervention 
closure of patent foramen ovale
It is recommended to perform clinical and echocardiographic (TTE) examinations on 
day 1, 4–6 weeks, 6, and 12 months after transcatheter PFO closure.
Prophylaxis of infective endocarditis should be used for 6 months after the procedure, 
and lifetime prophylaxis should be considered in patients with persistent residual 
leakage or other defects (eg, mitral regurgitation).
Return to full physical activity including playing sports is allowed in uncomplicated 
cases 4 weeks after the implantation of the device.
MRI is safe (1.5–3 T devices) 6 weeks after implantation of the occluder containing nitinol.
Abbreviations: see TAbleS 1–3
Table 9 Recommendations for the training of operators performing 
percutaneous patent foramen ovale closure
It is recommended that the operator undergoing training in transcatheter PFO closure 
should first conclude a complete theoretical training on indications, patient 
preparation, perioperative pharmacotherapy, as well as possible complications and 
their treatment.
The trainee operator should perform a minimum of 15 PFO closure procedures 
independently, under supervision, to acquire practical skills.
It is recommended that in a center that concluded less than 25 PFO closure 
procedures, the procedures should be performed in the presence of an experienced 
operator (proctor) to train the personnel and to avoid complications during the first 
procedures.
Abbreviations: see TAble 2
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